The MedTech industry is evolving and increasingly becoming subject to regulation and governmental scrutiny, resulting in unique legal and business challenges that present both substantial risk and reward.
Arnold & Porter partners Hemmie Chang and Phil Desjardins and senior associate Phil DeFedele will discuss how to mitigate and address major FDA regulatory, compliance, and business risks in MedTech transactions through effective due diligence and contractual and operational strategies. Whether you are focused on MedTech M&A or licensing deals, this program will provide you with insights on how to navigate these complex regulatory and business issues.
Webinar Series Alert
Part IV: IP Strategies for MedTech
Thursday, May 22
11 a.m.-noon ET